26th April 2027 | 9:30am EDT / 6:30am PDT / 2:30pm BST / 3:30pm CEST | Dr. Anthony Blaszczyk, Principal Scientist in the Global Biologics Department at U.S. Pharmacopeia, Lili Belcastro, PhD. Associate Director, Raw Materials, Drug Product Process Development at Bristol Myers Squibb |BOOK FREE SEAT FOR THIS WEBINAR
Analytical methods continue to evolve rapidly to meet the evolving needs of new therapeutic modalities. Emerging analytical platforms often utilize different measurement principles, making direct comparison difficult and leading to lack of concordance. Bridging between methods requires comparative studies and a well characterized reference material or control. This talk will outline considerations for design and analysis of such studies using case studies from the mAb and AAV gene therapy fields
Presented by Dr. Anthony Blaszczyk, Principal Scientist in the Global Biologics Department at U.S. Pharmacopeia

Dr. Anthony Blaszczyk is a Principal Scientist in the Global Biologics Department at U.S. Pharmacopeia (USP), where he leads initiatives within the Pipeline Development group to advance standards for Cell and Gene Therapy (CGT). His work focuses on the development of both documentary and physical standards that support product quality and innovation. He plays a pivotal role in USP’s efforts to meet evolving industry needs through collaboration with scientific experts and stakeholders across the biopharmaceutical sector. Prior to joining USP, Anthony earned his Ph.D. in Biochemistry from Penn State University. He previously managed an Analytical Development team at Catalent’s Gaithersburg and Rockville sites, where he specialized in method development, qualification, and method transfer to support AAV-based gene therapy production.
Lili Belcastro, PhD. Associate Director, Raw Materials, Drug Product Process Development at Bristol Myers Squibb

Lili Belcastro, PhD, is Associate Director of Early Development Raw Materials at Bristol Myers Squibb and Chair of the United States Pharmacopeia (USP) BIO4 Cell and Gene Therapies Expert Committee. She specializes in raw and starting materials used in advanced therapies, including plasmid DNA, AAV, and other viral vectors, ancillary materials, and single-use technologies. Her experience spans the development lifecycle, from material selection and risk assessment through qualification, specification development, supplier management, analytical testing, regulatory strategy, and lifecycle management.
Lili has contributed extensively to industry and compendial standards for cell and gene therapy through USP, ISO, BioPhorum, SCB, and ANSI, including previous service on the USP Plasmid DNA Expert Panel. She has authored publications and delivered numerous presentations on plasmid DNA, raw and starting materials, ancillary materials, and regulatory expectations for cell and gene therapy manufacturing. In addition to her industry and standards work, Lili is Adjunct Faculty at Saint Joseph’s University, teaching graduate-level regulatory science focused on biologics and cell and gene therapies. She holds a PhD in Cancer Biology and a BS in Pharmacology and Toxicology from the University of the Sciences in Philadelphia.
We will not sell your information to a third party. See our Privacy Policy